Abstract
A potential antimalarial prospect should have high efficacy with low toxicity. SynriamTM antimalarial drug has been proven to be safe and effective for the treatment of malaria in human with dearth information on rats. This study investigated its potential toxicity from prolonged administration on lipid profiles and haematological indices in rats. Thirty-five Wistar rats were randomized into five groups (A – E) of seven rats each. Animals in group A (control) received 0.5 mL distilled water, while groups B, C, D, and E respectively received 4.0, 8.0, 16.0 and 32.0 mg/kg bwt of the drug once daily for 28 days. The concentrations of serum TC, LDL and atherogenic index showed significant (p<0.05) decrease, while serum TRIG, HDL, and VLDL concentrations had no effect (p>0.05). The drug also had no effect (p>0.05) on the levels of the red blood cell count, PCV, Hb, MCV, MCH, and MCHC. Similarly, it had no effect (p>0.05) on the levels of the WBC, lymphocytes and neutrocytes, while the platelet counts had slight (p<0.05) decrease. Hence, SynriamTM is relatively safe at doses of 4.0-32.0 mg/kg bwt in rats when taken once daily with minimal effects on the lipid profiles and haematological indices.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
